Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Consumer OTC Drugs

Perrigo Anticipates FTC Settlement Will Resolve Ibuprofen Investigation

This article was originally published in The Tan Sheet

  • News
  • The Tan Sheet

Executive Summary

Perrigo has recorded a $4.7 mil. charge in its fiscal fourth quarter in anticipation of settling a Federal Trade Commission investigation related to an ibuprofen product

You may also be interested in...



FTC Settlement May Portend Antitrust Scrutiny Of ANDA First-Filer Deals

The Federal Trade Commission's settlement with Perrigo and Alpharma suggests that deals struck between competing first-to-file generic drug manufacturers may trigger future antitrust scrutiny

FTC Settlement May Portend Antitrust Scrutiny Of ANDA First-Filer Deals

The Federal Trade Commission's settlement with Perrigo and Alpharma suggests that deals struck between competing first-to-file generic drug manufacturers may trigger future antitrust scrutiny

FTC Settlement May Portend Antitrust Scrutiny Of ANDA First-Filer Deals

The Federal Trade Commission's settlement with Perrigo and Alpharma suggests that deals struck between competing first-to-file generic drug manufacturers may trigger future antitrust scrutiny

Table

View full table

Topics

Tags:
Consumer OTC Drugs
Latest Headlines

Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification

US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios

FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says

New EU Filings

See All
UsernamePublicRestriction

Register

PS097150

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By